Clinical trial
A Phase II Study to Determine the Safety, Efficacy, and Pharmacokinetics of Multiple Intravenous Doses of ALD518 80 mg, 160 mg, and 320 mg Versus Placebo Administered to Patients With Non-Small Cell Lung Cancer-Related Fatigue and Cachexia
NCT00866970 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study to Determine the Safety, Efficacy, and Pharmacokinetics of Multiple Intravenous Doses of ALD518 80 mg, 160 mg, and 320 mg Versus Placebo Administered to Patients With Non-Small Cell Lung Cancer-Related Fatigue and Cachexia
- Lead sponsor
- CSL Behring
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2008
- Completion date
- December 31, 2009
- Enrollment
- 124 (actual)
- Sites
- 43
Conditions
As the registry lists them; a condition with its own page is linked.